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Abstract
Background: Most systematic reviews conclude that another clinical trial is needed. Measures of sufficiency and
stability may indicate whether this is true.
Objectives: To show how evidence accumulated on centre-based versus home-based cardiac rehabilitation,
including estimates of sufficiency and stability
Methods: Systematic reviews of clinical trials of home versus centre-based cardiac rehabilitation were used to
develop a cumulative meta-analysis over time. We calculated the standardised mean difference (SMD) in effect,
confidence intervals and indicators of sufficiency and stability. Sufficiency refers to whether the meta-analytic
database adequately demonstrates that an intervention works - is statistically superior to another. It does this by
assessing the number of studies with null results that would be required to make the meta-analytic effect non-
statistically significant. Stability refers to whether the direction and size of the effect is stable as new studies are
added to the meta-analysis.
Results: The standardised mean effect difference reduced over fourteen comparisons from a non-significant
difference favouring home-based cardiac rehabilitation to a very small difference favouring hospital (SMD -0.10,
95% CI -0.32 to 0.13). This difference did not reach the sufficiency threshold (failsafe ratio 0.039 < 1) but did
achieve the criteria for stability (cumulative slope 0.003 < 0.005).
Conclusions: The evidence points to a relatively small effect difference which was stable but not sufficient in
terms of the suggested thresholds. Sufficiency should arguably be based on substantive significance and decided
by patients. Research on patient preferences should be the priority. Sufficiency and stability measures are useful
tools that need to be tested in further case studies.
Background
Any one clinical trial is seldom definitive by itself. Few
innovative technologies have sufficient effect to be
adopted on the basis of a single trial (or even without).
The FDA normally authorises market access for a new
drug or device based on two (or more) confirmatory
trials. Evidence usually accumulates in systematic
reviews and meta-analyses. Public decision making
bodies such as National Institute for Health & Clinical
Excellence (NICE) rely heavily on these methods. Most
systematic reviews conclude that more clinical trials are
needed.
Funders of non-commercial trials [1] need to consider
both the state of existing knowledge and the contribu-
tion any proposed trial would make. Cumulative meta-
analysis which shows the contribution of each trial has
been used since 1981 [2]. Lau and Schmid et al in 1995
used it to show that more than 34,000 patients had
been unnecessarily randomised into streptokinase trials
for acute myocardial infarction[3].
Methods to aid the interpretation of cumulative meta-
analysis have aimed to show when has sufficient infor-
mation been obtained. Pogue and Yusuf in 1997 pro-
posed using sequential monitoring boundaries with
cumulative meta-analysis to assess when evidence is
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“statistically significant and medically convincing” imply-
ing additional research is not needed [4]. Such bound-
aries mitigate the multiplicity issues that arise from
cumulative meta-analysis doing repeated analyses. Muel-
lerleile et al in 2006 proposed an alternative method
which involves calculating indicators of sufficiency and
stability. Sufficiency refers to “whether the meta-analytic
database adequately demonstrates that a public health
intervention works” and stability “refers to the shifts over
time in the accruing evidence about whether a public
health intervention works” [5]. Muellerleile et al argued
that stability (whether an effect has become stable across
waves in a cumulative meta-analysis) was not covered by
Pogue and Yusuf and their method is simpler due to not
requiring prior specification of the optimum information
size (which requires a researcher to have extensive
knowledge of the observed results of the accumulated
research before undertaking a cumulative meta-analysis).
More recently, in 2008 Wetterslev et al developed
Pogue and Yusuf’s method by recommending ways of
calculating the optimum information size for sequential
monitoring boundaries [6].
This paper applies cumulative meta-analysis and
Muellerleile’s indicators of sufficiency and stability to
twelve randomised clinical trials comparing centre-based
to home-based cardiac rehabilitation between 1985 and
2007. Cardiac rehabilitation was the subject of two sys-
tematic reviews [7,8] as well as a large clinical trial in
which several of the authors of this paper were involved
[9,10]. We were interested in identifying the contribu-
tion of that trial to the meta-analysis and exploring
research priorities.
Aims
1. To apply cumulative meta-analysis to trials of cen-
tre-based versus home based cardiac rehabilitation,
and
2. To explore using indicators of sufficiency and sta-
bility in assessing research priorities
Methods
Identification of studies and data extraction
We included trials identified in two previous systematic
reviews [7,8,11], on home based versus centre based car-
diac rehabilitation. Data extracted from these reviews
included details of the trial design, participants, inter-
ventions, outcome measures, method of measurement of
exercise capacity, results for each arm and standardised
mean difference and 95% confidence interval. All data
were checked against the original articles and the stan-
dardised mean difference and associated standard error
re-calculated to check it was correct, with additional
details provided by the authors. Country of trial and
funder was extracted from the original trial articles. The
Cochrane review defined home-based cardiac rehabilita-
tion as “a structured programme, with clear objectives
for the participants, including monitoring, follow-up, vis-
its, letters, telephone calls from staff, or at least self mon-
itoring diaries” and. centre-based cardiac rehabilitation
as “a supervised group based programme undertaken in
a hospital or community setting such as a sports
centre”[7].
Outcome measures
Our analysis was exercise capacity, the only outcome
common to all trials identified in the systematic reviews.
As trials reported exercise capacity in different ways, fol-
lowing the Cochrane review, we calculated the standar-
dised mean difference in exercise capacity at follow up
for home based rehabilitation compared to centre based
rehabilitation using hedges adjusted g [12]. As some of
the studies included were relatively small Hedges
adjusted g was used [8].
Cumulative meta-analysis
Cumulative meta-analysis involved updating the meta-
analysis as each trial reported to show how the evidence
evolved over time.
Statistical-analysis
As in the Cochrane systematic review, the between-
group differences in exercise capacity were pooled using
a random effects model because of the significant clini-
cal and statistical heterogeneity across trials. A sub-
group analysis looked at those RCTs conducted in the
UK.
Sufficiency was assessed by calculating the failsafe
ratio as each new trial joined the cumulative meta-ana-
lysis [5]. The failsafe ratio is a measure of the number
of studies with null results required to make the meta-
analytic result non-statistically significant, versus the sta-
tistical significance (weight) of the evidence available
already (see appendix 1 for further details). We used
Muellerleile’s suggested threshold for sufficiency, that is
a Failsafe ratio exceeding 1 implied sufficient evidence
that one form of rehabilitation was more effective than
the other and that additional research was unlikely to
change the weight of the evidence.
Stability was assessed by calculating the cumulative
slope of the regression line of the cumulative meta-ana-
lysis results repeated over time [5]. Muellerleiles’ sug-
gested criteria, that is the cumulative slope estimate
from the linear regression was less than 0.005, was used
to decide if the meta-analysis was stable.
Publication bias was assessed using Begg funnel plots
and by testing for funnel plot asymmetry using the
Egger weighted regression test.
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All statistical analyses were performed in Stata 10
(StataCorp, College Station, TX, USA).
Results
Included studies
The two systematic reviews included twelve studies
identified up to January 2008 [9,10,13-23]. To the best
of our knowledge no further relevant RCTs have been
published (confirmed by a MEDLINE search on the 26th
August 2010).
Most of the trials included patients at low risk of
another event following an acute myocardial infarction
or revascularisation, excluding those with severe
arrhythmias, ischemia, or heart failure [7]. Two studies
included patients with New York Heart Association
class 2 or 3 heart failure [18,21]
The trials involved a wide range of cardiac rehabilita-
tion programmes which differed in frequency, duration
and session length. The centre based programmes
usually involved supervised exercise on cycles and tread-
mills. Home based rehabilitation typically focused on
walking with support from a nurse or exercise specialist
on the telephone. Seven studies compared comprehen-
sive programmes whereas five included exercise only
based programmes (table 1). A detailed description of
the interventions included in each study can be found in
Dalal et al 2010 Table three at this web link http://www.
bmj.com/content/340/bmj.b5631/T3.expansion.html.
The twelve studies included 14 comparisons involving
1,557 patients (Table 1). The individual study results
(Figure 1) varied with six favouring centre-based cardiac
rehabilitation, six favouring home and 2 favouring
neither. The pooled standardised mean difference in
exercise capacity was not statistically significant (random
effects: SMD -0.11, 95% CI -0.35 to 0.13) (figure 1).
There was evidence of high levels of statistical heteroge-
neity between the study results across trials. The funnel
plot and associated egger regression test did not indicate
evidence of small study publication bias (p-value = 0.77).
Evolution of evidence - cumulative meta-analysis
The cumulative meta-analysis of the 14 comparisons
showed the effect size and confidence interval narrowing
over time, with the effect size initially favouring centre-
based cardiac rehabilitation and reducing over time
towards the line of no difference (figure 2). All trials
except Kassaian [18] contributed to the narrowing of
the confidence interval. The trend over time highlights
Kassaian as a potential outlier a point also highlighted
by the authors of the Cochrane review. They stated
there was uncertainty due to lack of detailed reporting
as to whether Kassaian compared hospital based rehabi-
litation to usual care instead of home based
rehabilitation.
Despite BRUM being the largest and latest trial its
contribution to the meta-analysis was limited to redu-
cing the width of the confidence interval without chan-
ging the point estimate (the pooled SMD in exercise
capacity prior to BRUM being published in 2007 was
-0.11 (95% CI -0.39 to 0.17), post BRUM was -0.11 (95%
CI -0.35 to 0.13)). The difference of -0.11 is equivalent
to approximately -0.34 of a MET.
Sufficiency and Stability
Figure 3 rotates figure 2 so that the slope of the mean
effect indicates stability. Stability (around a null effect)
was established after the results from Wu were published
in 2006, 1 year before BRUM (stability 0.004 from figure 3
in 2006). This conclusion is consistent with how the
point estimate in the cumulative meta-analysis changed
with the addition of new studies, BRUM was the first
study where the point estimate didn’t change (was stable
at -0.11, before and after inclusion of BRUM). Stability
means that further studies are unlikely to change the
aggregate picture, in this case, of a small difference.
The sufficiency indicator in figure 3 highlights two key
trials: Kassaian and Dalal. Dalal’s significant result
favouring home based rehabilitation compensated for
Kassaian’s significant result favouring centre-based. The
weight of evidence against the null hypothesis was
strongest after the publication of Kassaian, although not
sufficient (failsafe ratio = 0.321 < 1) or statistically sig-
nificant and reduced greatly after inclusion of Dalal (fail-
safe ratio = -0.045). Sufficiency in figure 3 did not
achieve Muellerleile’s threshold (failsafe ratio < 1
throughout), which is unsurprising given the lack of sta-
tistical significance.
Sensitivity analysis excluding Kassaian
Because of the uncertainty as to whether Kassaian
included usual care or home based rehabilitation we
conducted all analyses with and without this trial (Addi-
tional File 1 and Additional File 2). The only difference
was that the cumulative meta-analysis became stable
earlier (after inclusion of Gordon-Community) and then
unstable after inclusion of Dalal (Additional File 1 - sta-
bility indicator = 0.0063 just greater than 0.005). All
trials except Dalal contributed to the narrowing of the
confidence interval over time centering on zero. Both of
these are perhaps unsurprising given Dalal is the trial
included with the most extreme result (except for
DeBusk-Extended whose result is slightly more extreme
but less precise).
Discussion
What does this study show?
This is the first attempt to apply these methods (cumu-
lative meta-analysis and indicators of sufficiency and
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Table 1 Individual study results
Publication Home based CR Hospital based CR Difference
Author Country
of trial
Funder Year Type of
intervention
evaluated*
Type of
exercise
capacity
outcome and
primary
outcome
Mean SD n Mean SD n SMD SE
of
SMD
DeBusk-Brief
[17]
USA National Heart, Lung
and Blood Institute,
Bethesda, Maryland
and PepsiCo
Foundation, Purchase,
New York
1985 Exercise based
intervention
only
METs (primary
outcome not
defined)
8 1.5 33 7.9 1.3 31 0.07 0.25
DeBusk-
Extended
[17]
USA As above 1985 Exercise based
intervention
only
As above 7.9 1.5 33 8.9 1.4 30 -0.68 0.26
Sparks [20] USA Not stated. Authors
from Saint Vincent
Charity Hospital,
Cleaveland State
University; Saint
Thomas Hospital,
Nashville; and Ball State
University, Muncie
1993 Exercise based
intervention
only
Peak VO2 max
(primary
outcome not
defined)
1900 400 10 1950 150 10 -0.16 0.45
Bell [14] UK British Heart
Foundation
1998 Comprehensive Primary
outcome
exercise
capacity (METs).
7.29 2.8 91 7.1 3.1 91 0.06 0.15
Carlson [22] USA Blodgett Memorial
Medical Center
Research Fund, East
Grand Rapids,
Michagan; the Kent
Country Health
Department
Cardiovascular Mini-
Grant and the Merck
Pharmaceutical
Educational Grant,
Grand Rapids,
Michagan
2000 Comprehensive,
Home CR
included short
initial period of
centre based
intervention
Primary
outcome peak
functional
capacity (METs),
7.4 1.5 34 6.8 1.7 29 0.37 0.26
Kassaian
[18]
Iran Not stated. Authors
from Cardiovascular
Medical Center, Vali-
Asr-Ave, Tehran, Iran
2000 Exercise based
intervention
only
Functional
capacity (METs)
(primary
outcome not
defined)
8.9 2.9 60 12.4 2.7 65 -1.24 0.20
Arthur [13] Canada Heart and Stroke
Foundation of Ontario
2002 Exercise based
intervention
only
Primary
outcome
exercise
capacity (METs)
5.22 2.1 113 5.21 2 109 0.00 0.13
Gordon -
Community
[23]
USA American Heart
Association Patient
Care and Outcomes
Research Programme
Grant, Dallas, Texas
2002 Comprehensive,
Home CR
included short
initial period of
centre based
intervention
Maximal
oxygen uptake
(primary
outcome not
defined)
1.6 2.2 40 1.6 2.1 22 0.00 0.27
Gordon -
Supervised
[23]
USA As above 2002 As above As above 0.9 1.9 49 1.6 2.1 22 -0.35 0.26
Marcionni
[19]
Italy National Research
Council, the University
of Florence, and the
Regional Government
of Tuscany, Italy
2003 Comprehensive Primary
outcome total
work capacity
3650.7 3957.2 74 3509.3 3343.8 79 0.04 0.09
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stability) to trials of cardiac rehabilitation. The trials
included in this meta-analysis all contributed to redu-
cing the difference and uncertainty in exercise capacity
of home versus centre based rehabilitation. Kassaian and
Dalal were the most influential because they had the
most extreme results. The standardised mean difference
continued to favour centre over home based rehabilita-
tion but the size of that difference has narrowed over
time, from 0.27 to 0.11. The confidence interval
remained wide enough to include small to moderate dif-
ferences [24].
The decision by the NIHR HTA programme to com-
mission the BRUM trial in 2000 appears justified given
that evidence available on the relative benefits of centre
versus home based cardiac rehabilitation at the time was
neither stable nor sufficient and included the possibility
of large effect sizes (+/- 0.8 Cohen’s criteria [24] - figure
2 cumulative SMD in 2000 -0.27, 95% CI -0.81,0.26). Of
the six randomised controlled trials involving 517
patients that were available at this time (figure 1 studies
before 2001) [14,17,18,20,22] only one of these had been
conducted in the UK [14]. In 2007 just before BRUM
published a further six similar trials had reported from
six different countries [13,15,16,19,21,23]: USA, Canada,
Italy, Turkey, UK and China. The HTA programme
could not have known about these trials since trial
registration of clinical trials only commenced on a
voluntary basis in 2004 [25]. However even if these trials
had been known of, it is not clear that they could have
substituted for BRUM due to differences such as the
form of home based rehabilitation [7], and trial size and
duration.
Comparisons with other studies
The indicators of sufficiency and stability presented here
have been previously applied to five other case studies
[5,26]. Two of these found the results were sufficient
and stable. In the other three, the results were similar to
ours - stable but not sufficient, with the estimate center-
ing around the null effect and accumulating evidence
simply narrowing the confidence interval around that
null effect. In these three cases the authors concluded
that carrying out further research in the area would be
paramount to “flogging a dead horse”, with further stu-
dies unlikely to change the aggregate picture of a small
effect.
Limitations
The methodological focus of this paper had to do with
assessing sufficiency and stability indicators using a case
study in cardiac rehabilitation. The case study had two
main limitations. The first was the heterogeneity of the
Table 1 Individual study results (Continued)
Daskapan
[16]
Turkey Department of Physical
Therapy in Ankara
University, Faculty of
Medicine, Turkey
2005 Comprehensive,
Home CR
included short
initial period of
centre based
intervention
Exercise
capacity (ml/kg/
min) (primary
outcome not
defined)
23.6 7.4 11 23.3 6.8 11 0.04 0.43
Dalal [15] UK NHS Executive South
West (Research and
Development)
2006 Comprehensive Secondary
outcome
exercise
capacity (METs)
Primary
outcome
quality of life
(MacNew
questionnaire)
9.7 3.1 60 7.7 2.8 44 0.66 0.20
Wu [21] China Not stated. Authors
from Department of
Physical Medicine and
Rehabilitation,
Taichung Veterans
General Hospital,
Taichung, Taiwan
2006 Exercise based
intervention
only
Exercise
capacity (METs)
(primary
outcome not
defined)
22.9 3.6 18 24.2 4.4 18 -0.32 0.34
Jolly (BRUM)
[9,10]
UK UK Department of
Health, through the
HTA programme
2007 Comprehensive Primary
outcome
incremental
shuttle walking
test
391.3 162.1 191 407.4 157.6 179 -0.10 0.10
*Comprehensive = interventions evaluated included exercise plus education or psychological management or both. A detailed description of the hospital based
and home based intervention used by each study can be found in Dalal 2010 at this link http://www.bmj.com/content/340/bmj.b5631/T3.expansion.html. SD =
Standard deviation, CR = Cardiac Rehabilitation, SMD = standardised mean difference (hedges g), SE = Standard error, METs = metabolic equivalent, VO2 max =
maximum volume of oxygen.
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types of home and centre based rehabilitation included
within the trials. However, these trials were combined in
a meta-analysis of exercise capacity in exactly the same
way in the Cochrane systematic review and a meta-ana-
lysis confined to the three UK trials which used the
heart manual [27] for home based rehabilitation
[9,14,15] found three was too few for the sufficiency and
stability analysis. The second limitation was the focus
on a single outcome, exercise capacity, the only outcome
common to all trials identified in the Cochrane review.
However, exercise capacity is arguable the most plausi-
ble and key outcome for rehabilitation trials. Mortality
data was only available from four studies and is likely to
be confounded by drug treatment/uptake.
The results from a single case study have limited gen-
eralisability. More research is needed to better under-
stand these indicators and the usefulness of the
sufficiency indicator when applied to superiority com-
parisons showing differences close to zero. More case
studies, simulations and Bayesian methods may be use-
ful for this.
Unanswered questions and future research
As all the trials included in this analysis were designed
as superiority trials, we cannot conclude home based
and centre based cardiac rehabilitation are equivalent.
However, the above analyses show the difference in
effect were relatively small and stable. Other factors
have been shown to be important such as patient prefer-
ences [15]. The key question is what effect patients
would consider worthwhile. Is the standardised mean
difference of 0.11 sufficient for patients to choose one
form of rehabilitation or the other. Only a study of
patient preferences could answer this question.
Conclusions
The methods used here seem promising and have impli-
cations for researchers, treating clinicians, payers,
NOTE: Weights are from random effects analysis
Overall  (I-squared = 78.6%, p < 0.0001)
Dalal
Bell
Carlson
Sparks
Arthur
DeBusk-Brief
BRUM
Daskapan
DeBusk-Extended
Gordon-Supervised
Study
Wu
Kassaian
Marcionni
Gordon-Community
2006
1998
2000
1993
2002
1985
2007
2005
1985
2002
year
2006
Publication
2000
2003
2002
104
182
63
20
222
64
370
22
63
71
N
36
125
153
62
-0.11 (-0.35, 0.13)
0.66 (0.26, 1.06)
0.06 (-0.23, 0.35)
0.37 (-0.13, 0.87)
-0.16 (-1.04, 0.72)
0.00 (-0.26, 0.27)
0.07 (-0.42, 0.56)
-0.10 (-0.30, 0.10)
0.04 (-0.80, 0.88)
-0.68 (-1.19, -0.17)
-0.35 (-0.86, 0.15)
SMD (95% CI)
-0.32 (-0.97, 0.34)
-1.24 (-1.63, -0.86)
0.04 (-0.28, 0.36)
0.00 (-0.52, 0.52)
100.00
7.80
8.72
6.93
4.22
8.93
7.02
9.34
4.46
6.85
6.88
Weight
5.65
%
7.94
8.50
6.76
Favours Hospital CR  Favours Home CR 
0-1.5 -1 -.5 .5 1 1.5
Figure 1 Meta-analysis of studies published up to January 2008 comparing centre based versus home based cardiac rehabilitation -
random effects model. 1. SMD = standardised mean difference (hedges g).
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funders, sponsors, editors, ethics boards, patients, and
the public. Sufficiency and stability measures can be cal-
culated simply and shown graphically on a cumulative
meta-analysis figure. They provide useful tools for con-
sidering whether further research is needed and the
impact individual trials had on the meta-analysis. They
are relatively straight-forward to calculate but not yet
widely used. As with all meta-analyses, only published
studies available at the time searches are conducted can
be included. A policy-maker/funder wanting to use these
methods to make funding decisions/assess research prio-
rities would need to identify and consider ongoing stu-
dies. The thresholds suggested by Muellerleile et al are
arbitrary and require further testing. In particular, rather
than defining sufficiency mathematically with the focus
on statistical significance, the benchmark should be
based on substantive significance [28] set by patients’
preferences. More case studies and further work to
develop the sufficiency indicator would be helpful.
Appendix 1 - Calculation of the failsafe ratio for
assessment of sufficiency
The failsafe ratio is calculated as the sum of the Z
values from individual study results, compared to the
number of studies with null results that would be
required to make the meta-analytic result non-signifi-
cant. It was derived by Muellerleile and Mullen based
on Rosenthal’s file drawer analysis [5,29]. It provides
information about the amount of evidence against the
null hypothesis and whether this weight of evidence is
sufficient and unlikely to be changed with additional
research. It is calculated as follows:
FailsafeRatio =
((∑
Z
)2
1.6452
)
− ki
5ki + 10
Where Ki = the number of studies included in the
meta-analysis at wave i
DeBusk-Brief
DeBusk-Extended
Sparks
Bell
Carlson
Kassaian
Arthur
Gordon-Community
Gordon-Supervised
Marcionni
Daskapan
Dalal
Wu
BRUM
Study
1985
1985
1993
1998
2000
2000
2002
2002
2002
2003
2005
2006
2006
2007
Year
64
127
147
329
392
517
739
801
872
1025
1047
1151
1187
1557
patients
No. of
0.07 (-0.42, 0.56)
-0.30 (-1.04, 0.43)
-0.27 (-0.78, 0.24)
-0.15 (-0.51, 0.22)
-0.04 (-0.38, 0.29)
-0.27 (-0.81, 0.26)
-0.23 (-0.65, 0.19)
-0.20 (-0.58, 0.18)
-0.22 (-0.56, 0.12)
-0.19 (-0.49, 0.11)
-0.17 (-0.46, 0.11)
-0.10 (-0.39, 0.19)
-0.11 (-0.39, 0.17)
-0.11 (-0.35, 0.13)
0.78
0.42
0.30
0.43
0.80
0.32
0.29
0.30
0.21
0.22
0.23
0.51
0.43
0.36
P-valueCumulative Standardised Mean Difference (95% CI)
Favours Hospital CR  Favours Home CR 
0-1.5 -1 -.5 .5 1 1.5
Figure 2 Cumulative meta-analysis of studies published up to Jan 2008 comparing centre based versus home based cardiac
rehabilitation - random effects model. 1. The number of patients in this figure equals the cumulative number of patients included in each
meta-analysis.
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Additional material
Additional file 1: Sensitivity analysis - Cumulative meta-analysis of
studies excluding Kassaian. This file shows the cumulative meta-
analysis of studies published up to Jan 2008 comparing centre based
versus home based cardiac rehabilitation using a random effects model
and excluding Kassaian. The number of patients in this figure equals the
cumulative number of patients included in each meta-analysis
Additional file 2: Sensitivity analysis excluding Kassaian -
Cumulative meta-analysis from Additional File 1with indicators of
sufficiency and stability. This file shows the cumulative meta-analysis
from Additional File 1 with indicators of sufficiency (failsafe ratio) and
stability (cumulative slope). 1. SMD = standardised mean difference
(hedges g) 2. The cumulative SMD and 95% CI shown in this figure are
exactly the same as those shown in Additional File 1, 3. Threshold for
sufficiency > 1 (shown by red dashed line), not achieved in this
cumulative meta-analysis 4. Criteria for stability < 0.005, achieved in this
cumulative meta-analysis after inclusion of Arthur
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figure 2. 3. Threshold for sufficiency > 1 (shown by red dashed line), not achieved in this cumulative meta-analysis. 4. Criteria for stability < 0.005,
achieved in this cumulative meta-analysis after inclusion of Wu.
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